{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:11:07Z","timestamp":1765959067694},"reference-count":25,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Drug tolerability affects compliance. We evaluated the tolerability levels of azithromycin (750-mg loading dose plus 250 mg\/day;\n            <jats:italic>n<\/jats:italic>\n            = 148 subjects), doxycycline (100 mg\/day;\n            <jats:italic>n<\/jats:italic>\n            = 75), and placebo (\n            <jats:italic>n<\/jats:italic>\n            = 77) as prophylaxis against malaria in Indonesian adults over 20 weeks. Self-reported and elicited symptoms, health perception, hearing, hematology, and biochemistry were assessed. The loading dose was well tolerated. The frequencies (number per person-years [p-yr]) of all daily reported symptoms were similar in the three arms of the study: 40.2\/p-yr for azithromycin, 39.7\/p-yr for doxycycline, and 38.2\/p-yr for placebo. Relative to those who received placebo, azithromycin recipients complained more often of heartburn (rate ratio = 10.5 [95% confidence interval, 2.8 to 88.1]), paresthesia (2.03 [1.08 to 4.24]), and mild (1.55 [1.01 to 2.48]) and severe (11.2 [1.34 to \u221e]) itching but less often of fever (0.21 [0.09 to 0.49]) and tinnitus (0.09 [0.04 to 0.21]). Azithromycin recipients showed no evidence of clinical hearing loss or hematologic, hepatic, or renal toxicity. One azithromycin recipient developed an erythematous rash. Daily azithromycin was well tolerated by these Indonesian adults during 20 weeks of treatment.\n          <\/jats:p>","DOI":"10.1128\/aac.47.7.2199-2203.2003","type":"journal-article","created":{"date-parts":[[2003,6,23]],"date-time":"2003-06-23T19:17:06Z","timestamp":1056395826000},"page":"2199-2203","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Tolerability of Azithromycin as Malaria Prophylaxis in Adults in Northeast Papua, Indonesia"],"prefix":"10.1128","volume":"47","author":[{"given":"Walter R.","family":"Taylor","sequence":"first","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"},{"name":"Department of Tropical Medicine, Tulane University School of Public Health, New Orleans, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Fryauff","sequence":"additional","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Ohrt","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Picarima","sequence":"additional","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Biometrics, Walter Reed Army Institute of Research, Washington, D.C."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald S.","family":"Murphy","sequence":"additional","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendra","family":"Widjaja","sequence":"additional","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Braitman","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Materiel Development Activity, Fort Detrick, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliana","family":"Tjitra","sequence":"additional","affiliation":[{"name":"Centre for Health Research and Development, National Institutes of Health, Jakarta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asep","family":"Ganjar","sequence":"additional","affiliation":[{"name":"District Military Health Services, Jayapura, Papua, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor R.","family":"Jones","sequence":"additional","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Basri","sequence":"additional","affiliation":[{"name":"U.S. Naval Medical Research Unit No. 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Berman","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/516281"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0140-6736(93)91591-9","volume":"342","year":"1993","unstructured":"Bailey, R. L., P. Arullendran, H. C. Whittle, and D. C. W. Mabey. 1993. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet342:453-456.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/clinids\/24.5.958","volume":"24","year":"1997","unstructured":"Brown, B. A., D. E. Griffith, W. Girard, J. Levin, and R. J. Wallace. 1997. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin. Infect. Dis.24:958-964.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_5_2","first-page":"483","volume":"25","year":"2001","unstructured":"Cascaval, R. I., and D. J. Lancaster. 2001. Hypersensitivity syndrome associated with azithromycin. Am. J. Med.25:483-484.","journal-title":"Am. J. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oxfordjournals.aje.a112024","volume":"100","year":"1974","unstructured":"Ederer, F., and N. Mantel. 1974. Confidence limits on the ratio of two Poisson variables. Am. J. Epidemiol.100:165-167.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091208"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jac\/47.4.441","volume":"47","year":"2001","unstructured":"Ferwerda, A., H. A. Moll, W. C. Hop, J. M. Kouwenberg, C. V. Tjon Pian Gi, S. G. Robben, and R. de Groot 2001. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. J. Antimicrob. Chemother.47:441-446.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/bmj.312.7027.364","volume":"312","year":"1996","unstructured":"Glynn, R. J., and J. E. Buring. 1996. Ways of measuring rates of recurrent events. BMJ312:364-367.","journal-title":"BMJ"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/clinids\/23.5.983","volume":"23","year":"1996","unstructured":"Griffith, D. E., B. A. Brown, W. M. Girard, D. T. Murphy, and R. J. Wallace. 1996. Azithromycin activity against Mycobacterium avium complex lung disease in patients who are not infected with human immunodeficiency virus. Clin. Infect. Dis.23:983-989.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608083350604"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Hopkins S. 1996. Clinical toleration and safety of azithromycin. Am. J. Med. 91 (Suppl. 3A) : 40S-45S.","DOI":"10.1016\/0002-9343(91)90401-I"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/00006454-199504002-00009","volume":"14","year":"1995","unstructured":"Hopkins, S. J., and D. Williams. 1995. Clinical tolerability and safety of azithromycin in children. Pediatr. Infect. Dis. J.14:S67-S71.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_14_2","first-page":"563.","volume":"350","year":"1997","unstructured":"Hubner, C., A. Dietz, W. Stremmel, A. Stiehl, and K. Andrassy. 1997. Macrolide-induced Churg-Strauss syndrome in a patient with atopy. Lancet350:563.","journal-title":"Lancet"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2307\/2531405","volume":"40","year":"1984","unstructured":"Koopman, P. A. 1984. Confidence limits on the ratio of two proportions. Biometrics40:513-517.","journal-title":"Biometrics"},{"key":"e_1_3_2_16_2","first-page":"217","volume":"102","year":"1997","unstructured":"Longo, G., C. Valenti, G. Gandini, L. Ferrara, M. Bertesi, and G. Emilia. 1997. Azithromycin-induced intrahepatic cholestasis. Am. J. Med.102:217-218.","journal-title":"Am. J. Med."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209243271304"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/514566"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7139.1236"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/000348940010900416","volume":"109","year":"2000","unstructured":"Rees, B. D., and E. M. Gross. 2000. Irreversible sensineural hearing loss as a result of azithromycin ototoxicity. Ann. Otol. Rhinol. Laryngol.109:435-437.","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/BF01694511","volume":"22","year":"1977","unstructured":"Schneider, R. 1977. Doxycycline esophageal ulcers. Am. J. Dig. Dis.22:805-807.","journal-title":"Am. J. Dig. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/515071"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jac\/37.suppl_C.143","volume":"37","year":"1996","unstructured":"Treadway, G., and D. Pontani. 1996. Paediatric safety of azithromycin: worldwide experience. J. Antimicrob. Chemother.37(Suppl. C):143-149.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/clinids\/24.1.76","volume":"24","year":"1997","unstructured":"Tseng, A. L., L. Dolovich, and I. E. Salit. 1997. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Clin. Infect. Dis.24:76-77.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_25_2","first-page":"241.","volume":"343","year":"1994","unstructured":"Wallace, M. R., L. K. Miller, M. T. Nguyen, and A. R. Shields. 1994. Ototoxicity with azithromycin. Lancet343:241.","journal-title":"Lancet"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0891-5520(20)30694-2","volume":"9","year":"1995","unstructured":"Zuckerman, J. M., and K. M. Kaye. 1995. The newer macrolides. Infect. Dis. Clin. N. Am.9:731-745.","journal-title":"Infect. Dis. Clin. N. Am."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.7.2199-2203.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.7.2199-2203.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:22:42Z","timestamp":1645467762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.7.2199-2203.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1128\/AAC.47.7.2199-2203.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.7.2199-2203.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]},"assertion":[{"value":"2002-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}